import { EducationalContent } from '../../types';

export const CONTINUOUS_GLUCOSE_MONITORS: EducationalContent = {
  id: 'wearables-continuous-glucose-monitors',
  type: 'concept',
  name: 'Continuous Glucose Monitors (CGMs)',
  alternateNames: ['CGM', 'Continuous Glucose Monitoring', 'Real-Time Glucose Monitors', 'Glucose Sensors'],
  levels: {
    1: {
      level: 1,
      summary: 'Continuous glucose monitors are small devices worn on the body that automatically check blood sugar levels throughout the day and night without needing finger pricks.',
      explanation: 'For people with diabetes, knowing their blood sugar level is very important. In the past, they had to prick their finger several times a day to test a drop of blood. Continuous glucose monitors (CGMs) are a newer technology that makes this much easier. A CGM has a tiny sensor inserted just under the skin, usually on the belly or arm, that measures sugar levels in the fluid between cells. It checks your glucose every few minutes and sends the readings to a receiver, smartphone, or even a smartwatch. This means you can see your glucose level anytime just by looking at your device. CGMs also show arrows telling you if your glucose is going up, down, or staying steady, and they can alert you if your levels get too high or too low. Many people with diabetes find CGMs help them manage their condition better and feel more confident about their health.',
      keyTerms: [
        { term: 'blood sugar', definition: 'The amount of glucose (sugar) in your blood' },
        { term: 'diabetes', definition: 'A condition where the body has trouble controlling blood sugar' },
        { term: 'sensor', definition: 'A small device inserted under the skin that measures glucose' },
        { term: 'alerts', definition: 'Warnings when blood sugar gets too high or too low' },
        { term: 'finger pricks', definition: 'Traditional method of testing blood sugar with a drop of blood' },
      ],
    },
    2: {
      level: 2,
      summary: 'Continuous glucose monitors use subcutaneous sensors to measure interstitial glucose levels continuously, providing real-time data, trend information, and alerts that support diabetes self-management.',
      explanation: 'Continuous glucose monitoring (CGM) represents a significant advancement in diabetes management technology. The system consists of three main components: a small sensor inserted beneath the skin (typically lasting 7-14 days), a transmitter attached to the sensor that sends data wirelessly, and a receiver or smartphone app displaying glucose readings. CGMs measure glucose in interstitial fluid (the fluid between cells) rather than blood directly, with readings typically lagging blood glucose by 5-15 minutes. Modern CGMs provide readings every 1-5 minutes, creating a detailed picture of glucose patterns. Key features include trend arrows showing direction and rate of glucose change, customizable high and low glucose alerts, data sharing with caregivers or healthcare providers, and integration with insulin pumps in some systems. Clinical benefits include improved glycemic control (lower HbA1c), reduced hypoglycemia episodes, increased time in target glucose range, and better understanding of how food, activity, and medications affect glucose. CGMs are FDA-approved and covered by Medicare and many insurers for people with diabetes using insulin, with expanding indications for broader diabetes populations.',
      keyTerms: [
        { term: 'interstitial fluid', definition: 'Fluid between cells where CGM sensors measure glucose' },
        { term: 'trend arrows', definition: 'Indicators showing if glucose is rising, falling, or stable' },
        { term: 'glucose alerts', definition: 'Notifications when glucose levels reach set thresholds' },
        { term: 'HbA1c', definition: 'Measure of average blood sugar over 2-3 months' },
        { term: 'time in range', definition: 'Percentage of time glucose stays within target levels' },
        { term: 'insulin pump integration', definition: 'CGM data connecting with automated insulin delivery systems' },
      ],
    },
    3: {
      level: 3,
      summary: 'CGM systems employ electrochemical or optical sensing technologies to provide continuous interstitial glucose measurement, enabling advanced diabetes management through real-time data, predictive alerts, and automated insulin delivery integration.',
      explanation: 'CGM technology primarily utilizes enzymatic electrochemical sensing, where glucose oxidase catalyzes glucose reaction producing electrical current proportional to glucose concentration. Sensor accuracy is characterized by mean absolute relative difference (MARD) against reference blood glucose, with current devices achieving MARD values of 8-12%, enabling non-adjunctive use (treatment decisions without confirmatory fingersticks). Factory calibration has replaced user calibration in most current systems. Data transmission uses Bluetooth Low Energy to smartphones or dedicated receivers, with some systems enabling direct smartwatch display. Glucose data metrics include time in range (TIR, typically 70-180 mg/dL), time below range (TBR), time above range (TAR), glucose management indicator (GMI, estimated HbA1c equivalent), and glycemic variability measures. Predictive algorithms analyze glucose trends to alert users before reaching threshold values. Automated insulin delivery (AID) systems integrate CGM with insulin pumps, using control algorithms to adjust basal insulin delivery based on CGM readings, with advanced systems approaching closed-loop control. Clinical evidence from randomized trials demonstrates CGM benefits across diabetes populations, with strongest evidence in type 1 diabetes and insulin-requiring type 2 diabetes. Emerging applications include CGM use in hospital settings, pregnancy, and non-insulin-using type 2 diabetes.',
      keyTerms: [
        { term: 'glucose oxidase', definition: 'Enzyme in CGM sensors catalyzing glucose detection' },
        { term: 'MARD', definition: 'Mean absolute relative difference; measure of sensor accuracy' },
        { term: 'non-adjunctive use', definition: 'FDA approval for treatment decisions without fingerstick confirmation' },
        { term: 'time in range', definition: 'Key metric of glucose control typically targeting 70-180 mg/dL' },
        { term: 'glucose management indicator', definition: 'CGM-derived estimate of HbA1c' },
        { term: 'automated insulin delivery', definition: 'Systems adjusting insulin based on CGM readings' },
        { term: 'closed-loop', definition: 'Advanced systems approaching artificial pancreas functionality' },
        { term: 'glycemic variability', definition: 'Fluctuations in glucose levels over time' },
      ],
    },
    4: {
      level: 4,
      summary: 'Academic analysis of CGM encompasses sensor technology development, clinical outcomes research, health economics evaluation, behavioral diabetes management implications, and the evolution toward automated insulin delivery systems.',
      explanation: 'Scholarly examination of CGM spans biomedical engineering, clinical medicine, behavioral science, and health policy. Sensor technology research addresses performance optimization including accuracy improvement, extended wear duration, biocompatibility enhancement, and interference reduction from medications and physiological factors. Clinical outcomes research examines CGM efficacy across populations, with meta-analyses confirming HbA1c reduction and hypoglycemia prevention benefits, though effect sizes vary by baseline control and CGM utilization patterns. Time in range has emerged as a clinically meaningful metric correlating with long-term diabetes complications, with consensus targets established by international guidelines. Behavioral research examines how CGM data affects self-management decisions, identifying both benefits (informed dosing, pattern recognition) and challenges (data overload, alarm fatigue, diabetes distress). Health economics analyses evaluate cost-effectiveness, finding favorable results particularly when considering quality-of-life improvements and hypoglycemia reduction, though access disparities persist across insurance types and socioeconomic groups. The integration of CGM with insulin pump therapy has evolved toward automated insulin delivery systems, with control algorithms (proportional-integral-derivative, model predictive control) adjusting insulin delivery based on CGM inputs. Research continues toward fully closed-loop artificial pancreas systems requiring minimal user input. Data aggregation from CGM populations enables research on glucose patterns, treatment optimization, and real-world effectiveness.',
      keyTerms: [
        { term: 'sensor optimization', definition: 'Research improving accuracy, duration, and biocompatibility' },
        { term: 'meta-analysis', definition: 'Statistical synthesis of multiple CGM efficacy studies' },
        { term: 'time in range targets', definition: 'International consensus goals for glucose control' },
        { term: 'alarm fatigue', definition: 'Desensitization from excessive or unnecessary alerts' },
        { term: 'diabetes distress', definition: 'Emotional burden from diabetes management and data overload' },
        { term: 'cost-effectiveness', definition: 'Economic analysis of CGM value considering quality of life' },
        { term: 'model predictive control', definition: 'Algorithm anticipating glucose changes for insulin adjustment' },
        { term: 'artificial pancreas', definition: 'Fully automated closed-loop insulin delivery system' },
      ],
    },
    5: {
      level: 5,
      summary: 'Clinical management with CGM requires systematic approaches to patient selection, device education, data interpretation, therapy adjustment, and integration with comprehensive diabetes care plans.',
      explanation: 'Effective clinical utilization of CGM demands attention to patient selection, education, data management, and treatment optimization. Patient selection should consider glycemic management needs (frequent hypoglycemia, hypoglycemia unawareness, suboptimal HbA1c, significant glycemic variability), insulin regimen complexity, patient motivation and technological readiness, and insurance coverage. Comprehensive CGM education addresses sensor insertion technique, device operation, alert configuration, data interpretation, and troubleshooting common issues. Initial alert settings should balance sensitivity against alarm fatigue, with personalized adjustment over time. Data interpretation focuses on pattern identification: fasting glucose trends, postprandial excursions, overnight patterns, and responses to activity. Standardized CGM reports (ambulatory glucose profile) facilitate efficient clinical review of time in range, variability, and specific time-period patterns. Therapy adjustment based on CGM data may address insulin dosing (basal rates, correction factors, carbohydrate ratios), medication timing, dietary patterns, and activity management. Integration with automated insulin delivery systems requires additional education on system operation, alert management, and appropriate expectations. Quality metrics include time in range improvement, hypoglycemia reduction, and patient-reported outcomes including quality of life and diabetes distress. Ongoing support addresses technical troubleshooting, data review, and therapy optimization as patient needs evolve.',
      keyTerms: [
        { term: 'patient selection', definition: 'Identifying appropriate candidates based on clinical needs and readiness' },
        { term: 'CGM education', definition: 'Training on device use, data interpretation, and troubleshooting' },
        { term: 'alert configuration', definition: 'Setting personalized thresholds balancing safety and alarm fatigue' },
        { term: 'ambulatory glucose profile', definition: 'Standardized report format for efficient clinical review' },
        { term: 'pattern identification', definition: 'Recognizing trends in fasting, postprandial, and overnight glucose' },
        { term: 'therapy adjustment', definition: 'Modifying insulin, medications, diet, and activity based on CGM data' },
        { term: 'quality metrics', definition: 'Time in range, hypoglycemia events, and patient-reported outcomes' },
        { term: 'ongoing support', definition: 'Continued technical and clinical assistance as needs evolve' },
      ],
      clinicalNotes: 'When prescribing CGM, assess patient motivation, technological comfort, and insurance coverage. Provide comprehensive training on device use, data interpretation, and alert management. Review CGM data regularly, using ambulatory glucose profiles to identify patterns and guide therapy adjustments. Start with moderate alert thresholds, adjusting based on patient experience and clinical goals. Address alarm fatigue proactively. Integrate CGM into overall diabetes management, considering automated insulin delivery for appropriate candidates. Monitor time in range, hypoglycemia events, and patient quality of life as outcomes.',
    },
  },
  media: [],
  citations: [
    {
      id: 'battelino-2019',
      type: 'article',
      title: 'Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range',
      authors: ['Battelino T', 'et al.'],
      source: 'Diabetes Care',
      page: '42(8):1593-1603',
    },
    {
      id: 'beck-2017',
      type: 'article',
      title: 'Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial',
      authors: ['Beck RW', 'et al.'],
      source: 'JAMA',
      page: '317(4):371-378',
    },
    {
      id: 'ada-2023',
      type: 'article',
      title: '7. Diabetes Technology: Standards of Care in Diabetesâ€”2023',
      authors: ['American Diabetes Association'],
      source: 'Diabetes Care',
      page: '46(Suppl 1):S111-S127',
    },
    {
      id: 'rodbard-2016',
      type: 'article',
      title: 'Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities',
      authors: ['Rodbard D'],
      source: 'Diabetes Technol Ther',
      page: '18(Suppl 2):S3-S13',
    },
  ],
  crossReferences: [
    { targetId: 'chronic-disease-management-apps', targetType: 'concept', relationship: 'related', label: 'Chronic Disease Management Apps' },
    { targetId: 'remote-patient-monitoring', targetType: 'concept', relationship: 'related', label: 'Remote Patient Monitoring' },
    { targetId: 'cardiac-monitors', targetType: 'concept', relationship: 'related', label: 'Cardiac Monitors' },
    { targetId: 'health-data-privacy', targetType: 'concept', relationship: 'related', label: 'Health Data Privacy' },
  ],
  tags: {
    systems: ['digital-health'],
    topics: ['wearables', 'diabetes', 'glucose-monitoring', 'medical-devices', 'chronic-disease'],
    keywords: ['CGM', 'continuous glucose monitoring', 'diabetes technology', 'blood sugar', 'insulin pump', 'glucose sensor'],
  },
  createdAt: '2025-01-28T00:00:00.000Z',
  updatedAt: '2025-01-28T00:00:00.000Z',
  version: 1,
  status: 'published',
  contributors: ['Biological Self Content Team'],
};
